Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
In vitro studies with soman inhibited non
2022-11-03

In vitro studies with soman-inhibited, non-aged AChE revealed a species dependent reactivating potency of HI-6 and MMB-4. With guinea pig AChE second order reactivation rate constants of 0.051 and 0.038mM−1min−1 were determined for HI-6 and MMB-4, respectively (Luo et al., 2007). Corresponding value
-
br AD and COX LOX pharmacology Early studies
2022-11-03

AD and COX/5-LOX pharmacology Early studies on the role of cyclooxygenases in AD were inspired by epidemiological data suggesting that COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial in AD patients (Lucca et al., 1994, McGeer et al., 1990). This line of re
-
For the NSCLC patients with EGFR
2022-11-03

For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment
-
In conclusion AXL overexpression preexisted in a subgroup
2022-11-03

In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
-
Here the so called alkali assay is proposed as
2022-11-03

Here the so-called alkali assay [18] is proposed as a method to be applied directly on the purified recombinant enzyme sharing the same structural and functional features of the wild-type enzyme [19], [20], [21] using its physiological substrate androstenedione. The assay that was already successful
-
221 2 We found a protective effect of the GTCC haplotype
2022-11-03

We found a protective effect of the GTCC haplotype against ED, which is reflected by its association with increased IIEF in patients with clinical ED. Further studies are required to determine the functional implications of these genetic markers combined in specific haplotypes blocks. Indeed, we fou
-
Since immunoassays cannot specifically quantify
2022-11-03

Since immunoassays cannot specifically quantify each apelin peptide, a more reliable approach, mass spectrometry (MS) has been used recently to quantify and characterize apelin fragments in plasma. Using this technology, Zhen et al. showed that [Pyr-1]-apelin-13 was the major apelin form present in
-
it’s time The control group participants of the current stud
2022-11-01

The control group participants of the current study were very similar in age to those of Puertas et al. There was no significant correlation between age and enzyme activity over the short age span studied although age-related changes in the activity of ApA and aspartyl aminopeptidase, typically incr
-
br Current therapies for metabolic diseases
2022-11-01

Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
Thus far clinical data indicate that IDO inhibitors have
2022-11-01

Thus far, clinical data indicate that IDO1 inhibitors have manageable toxicity, albeit with a relatively short period of treatment in a small number of patients. KYN is a pluripotent mediator and key intermediate for the synthesis of a host of downstream KP metabolites that are implicated in inflamm
-
Despite hydrolysis with commercial enzymes like
2022-11-01

Despite hydrolysis with commercial enzymes like trypsin, pepsin, Alcalase, Flavourzyme and Thermolysin have been used to digest parent proteins and generate peptides, microbial fermentation by proteolytic species has also proved to be a successful strategy (Fakhfakh et al., 2013, Jemil et al., 2016,
-
Although we have achieved a great deal of success
2022-11-01

Although we have achieved a great deal of success in the development of tools to understand autophagy in health and disease, highly specific reagents for autophagy manipulation and deep knowledge of autophagy is required to advance the research in therapeutic treatment. Better disease (ischemia) ani
-
br The future of cancer
2022-11-01

The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor 3ma suggests that these
-
Our outcrossing data confirmed that ACL
2022-11-01

Our outcrossing data confirmed that ACL1 and ACL2 have important temporal and spatial functions in ascospore delimitation in G. zeae. When each ACL deletion mutant was used as male for outcrossing, nuclear division and spore delimitation were not properly progressed in most asci. Ascospores that con
-
br The role of apelin in respiratory diseases At present
2022-11-01

The role of apelin in respiratory diseases At present, several scientific studies have suggested that the apelin/APJ system may play an important role in the development of pulmonary diseases (Table 4). For example, in an experiment on rats suffering from acute lung injury, apelin-13 decreases th
15827 records 363/1056 page Previous Next First page 上5页 361362363364365 下5页 Last page